Business Description
LadRx Corp
NAICS : 325414
SIC : 2836
ISIN : US2328286081
Description
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 60.88 | |||||
| Equity-to-Asset | 0.05 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 7/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26.4 | |||||
| 3-Year EPS without NRI Growth Rate | 31.7 | |||||
| 3-Year Book Growth Rate | -79.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 12-1 Month Momentum % | -13.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.03 | |||||
| Quick Ratio | 1.03 | |||||
| Cash Ratio | 0.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.7 | |||||
| Shareholder Yield % | 15.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | 113.86 | |||||
| ROA % | 15.62 | |||||
| ROIC % | -1381.5 | |||||
| ROC (Joel Greenblatt) % | -2787.17 | |||||
| ROCE % | -1065.18 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 1.28 | |||||
| PB Ratio | 11.81 | |||||
| Price-to-Free-Cash-Flow | 1.25 | |||||
| Price-to-Operating-Cash-Flow | 1.25 | |||||
| EV-to-EBIT | 0.26 | |||||
| EV-to-EBITDA | 0.27 | |||||
| EV-to-FCF | -0.76 | |||||
| Earnings Yield (Greenblatt) % | 385.68 | |||||
| FCF Yield % | 96.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LadRx Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.146 | ||
| Beta | 1.24 | ||
| Volatility % | 25.24 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 0.056 | ||
| 12-1 Month Momentum % | -13.85 | ||
| 52-Week Range (€) | 0.05 - 0.145 | ||
| Shares Outstanding (Mil) | 0.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LadRx Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LadRx Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
LadRx Corp Frequently Asked Questions
What is LadRx Corp(STU:CX5)'s stock price today?
The current price of STU:CX5 is €0.06. The 52 week high of STU:CX5 is €0.14 and 52 week low is €0.05.
When is next earnings date of LadRx Corp(STU:CX5)?
The next earnings date of LadRx Corp(STU:CX5) is 2024-05-15 Est..
Does LadRx Corp(STU:CX5) pay dividends? If so, how much?
LadRx Corp(STU:CX5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers